Table 1.
Analysis of low grade glioma patients treated with LITT
| Study | Tumor grade (Number of patients) | Patientdemographics (M/F, age range) | Inoperable due to tumor location? (yes/no) | De novo or follow on LITT | Intra operative MRI guidance (yes/no) |
Adjuvant postoperative therapy? (yes/no) | Clinical results |
|---|---|---|---|---|---|---|---|
| Ascher [28] | II (2) |
1M/1F, 8 and 35 |
Yes | De novo | Yes | N/A |
Male pt at 4 years out showed no presence of tumor |
| Roux [29] |
I (2) II (2) |
2M/2F, 10–20 |
Yes | De novo | No | No | No perioperative morbidity/mortality |
| Kahn [30] | II (3) |
2M/1F, 29–68 |
Yes | De novo (1 follow on) | Yes | 2 no/1 yes | 3 months post-op LITT, lesion size decreased 15–87% (avg. 51%) |
| Kahn [31] | II (2) |
1M/1,: 40 and 27 |
Yes | De novo | Yes | No | No peri-procedural side effects noted |
| Schwabe [32] | II (11) |
7M/4F, 23–68 |
Yes (8/11) | De novo | No | No | Total lesion size decreased by 50% within 90 days in all patients. 7/18 pts had recurrence outside laser field (unknown f/up) |
| Leonardi [21] | II (7) |
Not specified, mean age: 46.9 |
Yes | De novo (6/7) | Yes | No |
Mean survival time: 34 months Mean time to progression: 16 months |
| Von Tempelhoff [33] | II (2) |
1M/1F, 30 and 40 |
Yes | De novo | Yes | No | No clinical or radiological recurrence at 28 month follow up |
| Jethwa [86] | I–II (3) | N/A, 13–58 | No | Follow on | Yes | No | Majority of patients discharged on post-operative day 1 |
| Patel NV [89] | I–II (4) | 2M/2F, 13–59 | Yes | De novo (2 follow on) | Yes | Fractionated radiation in 1 patient | Average recurrence time 4.4 months. 1 patient remained recurrence-free at 40 months |
| Patel NV [62] | I–II (7) | N/A, 10–82 | Unclear | Follow on | Yes | No | No peri-procedural morbidity |
| Buckley [37] | I (3) | 2M/1F, 7–18 | Yes | De novo (1 follow on) | Yes | Adjuvant everolimus in 2 patients | Durable clinical and radiographic tumor control in 2 of 3 cases |
| Dadey [38] | I (2) | 2F, 13 and 14 | No | De novo | Yes | No | Tumor shrinkage on 3-month MRI, stable clinically |
| Dadey [87] | I (2) | 1M/1F, 36 and 55 | Yes | De novo | Yes | No | 1 patient experienced post-op ophthalmoplegia and dysarthria, which resolved to neurologic baseline at 6 month follow up |
| Tovar-Spinosa [85] | I–II (11) | 6M/5F, 4–17 | Unclear | 6 De novo, 5 follow on | Yes | Adjuvant Everolimus in 1 patient | Only 1 patient showed signs of progression and was started on Everolimus |
| Patel [34] | I–II (23) | Not specified | Unclear | Follow on | Yes | No | 13.7% of patients had a post-op neurologic deficit; 64.3% of these had complete resolution of deficit at 1 month follow up |
| Miller [35] | I–II (6) | Not specified, 10–17 | Unclear | De novo | Yes | Adjuvant chemotherapy in 1 patient | All patients discharged on post-operative ay 0 or 1. Four patients demonstrated no recurrence on follow up to date |
| Rennert [5] | I–II (5) | Not specified, mean age: 50.7 | Yes (46% of lesions treated) | De novo | Yes | N/A | No perioperative morbidity |
| Karsy [36] | I (1) | 1M, 5 | No | De novo | Yes | No | No perioperative morbidity |
| Total | I–II (98) | Age range: 5–82 | Well tolerated overall |